The presented trial results, especially in MCI patients, are promising, particularly as Alzheon is targeting a subset of ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to such cells in non-immunized controls, regardless of whether the treatment was ...

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Recent successes with anti-amyloid monoclonal antibodies in treating early ... and molecular processes likely play a role as well, as Aβ may also lead to cognitive impairment via synapse damage ...

Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.